Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Protocol of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) to Evaluate the Safety and Immunogenicity in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years

NCT06675032 is registered in ClinicalTrials.gov with Reinovax Biologics Co., LTD as lead sponsor.

NCT NCT06675032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06675032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Protocol of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) to Evaluate the Safety and Immunogenicity in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Lead sponsor
Reinovax Biologics Co., LTD
Phase
Phase 1
Overall status
Completed
Start date
April 27, 2024
Completion date
April 14, 2026
Enrollment
230 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infectious disease